XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition
XingNaoJing injection (XNJ), extracted from a traditional compound Chinese medicine Angong niuhuang pill, is well known for treating stroke in the clinic, but the specific effects and mechanisms remain unclear. We investigated the mechanistic basis for the protective effect of XNJ on cerebral ischae...
Gespeichert in:
Veröffentlicht in: | Pharmaceutical biology 2020-01, Vol.58 (1), p.16-24 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 24 |
---|---|
container_issue | 1 |
container_start_page | 16 |
container_title | Pharmaceutical biology |
container_volume | 58 |
creator | Zhang, Yue-Ming Qu, Xiao-Yu Tao, Li-Na Zhai, Jing-Hui Gao, Huan Song, Yan-Qing Zhang, Si-Xi |
description | XingNaoJing injection (XNJ), extracted from a traditional compound Chinese medicine Angong niuhuang pill, is well known for treating stroke in the clinic, but the specific effects and mechanisms remain unclear.
We investigated the mechanistic basis for the protective effect of XNJ on cerebral ischaemia/reperfusion (I/R) injury.
Five groups of 10 SD rats underwent 2 h of middle cerebral artery occlusion (MCAO) followed by 24 h reperfusion. XNJ at 10 and 15 mL/kg was intraperitoneally administered 24 h before ischaemia and at the onset of reperfusion respectively. The silent information regulator 1 (SIRT1) inhibitor EX527 was intracerebroventricularly injected 0.5 h before reperfusion. Cerebral infarction size, neurological scores, morphological changes, and expression levels of inflammatory mediators and SIRT1 were measured. Furthermore, human brain microvascular endothelial cells (HBMECs) were subjected to 3 h oxygen and glucose deprivation (OGD) followed by 24 h reoxygenation to mimic cerebral I/R in vitro. EX527 pre-treatment occurred 1 h before OGD. SIRT1 and inflammatory mediator levels were analyzed.
Both XNJ doses significantly decreased cerebral infarct area (40.11% vs. 19.66% and 9.87%) and improved neurological scores and morphological changes. Inflammatory mediator levels were remarkably decreased in both model systems after XNJ treatment. XNJ also enhanced SIRT1 expression. Notably, the SIRT1 inhibitor EX527 attenuated the XNJ-mediated decrease in inflammation in vivo and in vitro.
XNJ improved cerebral I/R injury through inhibiting the inflammatory response via the SIRT1 pathway, which may be a useful target in treating cerebral I/R injury. |
doi_str_mv | 10.1080/13880209.2019.1698619 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_13880209_2019_1698619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5c5a3ab22f194df0bc63a67036a7d385</doaj_id><sourcerecordid>2509430119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c562t-fb849857e8125b466fb44efe33ac7eb9c4b96d8163e374297f033d1347b5d5bb3</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEoqXwE0CRuHDJ1t-xLwhU8bGoAgmKxM2ynfGuV0m8tZOiFX8eL7utKAdOtmaeecczfqvqOUYLjCQ6x1RKRJBaEITVAgslBVYPqlPcMtZwjMXDci9Ms4dOqic5bxBCnFL-uDqhWHJGCD-tfv0I4-qziZ_KUYdxA24KcazNAH2IyUyQawcJbDJ9HbJbGxiCOU-wheTnvEdL0Zx29U0w9bfl1yvcDNCFUtiVjO_NMJgplnyCvI1jhhJdBxv2XZ5Wj7zpMzw7nmfV9_fvri4-NpdfPiwv3l42jgsyNd5KpiRvQWLCLRPCW8bAA6XGtWCVY1aJTmJBgbaMqNYjSjtMWWt5x62lZ9XyoNtFs9HbFAaTdjqaoP8EYlppk6bgetDccUONJcRjxTqPrBPUiBZRYdqOSl60Xh-0trMtgzoYp7Kae6L3M2NY61W80UKJMgYuAq-OAilez5AnPZS9Qt-bEeKcNaFEtkxyRAr68h90E-c0llVpwpFiFGGsCsUPlEsx5wT-7jEY6b1V9K1V9N4q-miVUvfi70nuqm69UYA3B6D8Y0yD-RlT3-nJ7PqYfDKjC7nA_-3xG02e0Es</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2509430119</pqid></control><display><type>article</type><title>XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition</title><source>Taylor & Francis Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zhang, Yue-Ming ; Qu, Xiao-Yu ; Tao, Li-Na ; Zhai, Jing-Hui ; Gao, Huan ; Song, Yan-Qing ; Zhang, Si-Xi</creator><creatorcontrib>Zhang, Yue-Ming ; Qu, Xiao-Yu ; Tao, Li-Na ; Zhai, Jing-Hui ; Gao, Huan ; Song, Yan-Qing ; Zhang, Si-Xi</creatorcontrib><description>XingNaoJing injection (XNJ), extracted from a traditional compound Chinese medicine Angong niuhuang pill, is well known for treating stroke in the clinic, but the specific effects and mechanisms remain unclear.
We investigated the mechanistic basis for the protective effect of XNJ on cerebral ischaemia/reperfusion (I/R) injury.
Five groups of 10 SD rats underwent 2 h of middle cerebral artery occlusion (MCAO) followed by 24 h reperfusion. XNJ at 10 and 15 mL/kg was intraperitoneally administered 24 h before ischaemia and at the onset of reperfusion respectively. The silent information regulator 1 (SIRT1) inhibitor EX527 was intracerebroventricularly injected 0.5 h before reperfusion. Cerebral infarction size, neurological scores, morphological changes, and expression levels of inflammatory mediators and SIRT1 were measured. Furthermore, human brain microvascular endothelial cells (HBMECs) were subjected to 3 h oxygen and glucose deprivation (OGD) followed by 24 h reoxygenation to mimic cerebral I/R in vitro. EX527 pre-treatment occurred 1 h before OGD. SIRT1 and inflammatory mediator levels were analyzed.
Both XNJ doses significantly decreased cerebral infarct area (40.11% vs. 19.66% and 9.87%) and improved neurological scores and morphological changes. Inflammatory mediator levels were remarkably decreased in both model systems after XNJ treatment. XNJ also enhanced SIRT1 expression. Notably, the SIRT1 inhibitor EX527 attenuated the XNJ-mediated decrease in inflammation in vivo and in vitro.
XNJ improved cerebral I/R injury through inhibiting the inflammatory response via the SIRT1 pathway, which may be a useful target in treating cerebral I/R injury.</description><identifier>ISSN: 1388-0209</identifier><identifier>EISSN: 1744-5116</identifier><identifier>DOI: 10.1080/13880209.2019.1698619</identifier><identifier>PMID: 31854225</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Cerebral blood flow ; Cerebral infarction ; Chinese medicine ; Endothelial cells ; Inflammation ; Injection ; Ischemia ; Microvasculature ; Morphology ; pro-inflammatory response ; Reperfusion ; SIRT1 protein ; stroke</subject><ispartof>Pharmaceutical biology, 2020-01, Vol.58 (1), p.16-24</ispartof><rights>2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2019</rights><rights>2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2019 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c562t-fb849857e8125b466fb44efe33ac7eb9c4b96d8163e374297f033d1347b5d5bb3</citedby><cites>FETCH-LOGICAL-c562t-fb849857e8125b466fb44efe33ac7eb9c4b96d8163e374297f033d1347b5d5bb3</cites><orcidid>0000-0003-1685-6914</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968491/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968491/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27479,27901,27902,53766,53768,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31854225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Yue-Ming</creatorcontrib><creatorcontrib>Qu, Xiao-Yu</creatorcontrib><creatorcontrib>Tao, Li-Na</creatorcontrib><creatorcontrib>Zhai, Jing-Hui</creatorcontrib><creatorcontrib>Gao, Huan</creatorcontrib><creatorcontrib>Song, Yan-Qing</creatorcontrib><creatorcontrib>Zhang, Si-Xi</creatorcontrib><title>XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition</title><title>Pharmaceutical biology</title><addtitle>Pharm Biol</addtitle><description>XingNaoJing injection (XNJ), extracted from a traditional compound Chinese medicine Angong niuhuang pill, is well known for treating stroke in the clinic, but the specific effects and mechanisms remain unclear.
We investigated the mechanistic basis for the protective effect of XNJ on cerebral ischaemia/reperfusion (I/R) injury.
Five groups of 10 SD rats underwent 2 h of middle cerebral artery occlusion (MCAO) followed by 24 h reperfusion. XNJ at 10 and 15 mL/kg was intraperitoneally administered 24 h before ischaemia and at the onset of reperfusion respectively. The silent information regulator 1 (SIRT1) inhibitor EX527 was intracerebroventricularly injected 0.5 h before reperfusion. Cerebral infarction size, neurological scores, morphological changes, and expression levels of inflammatory mediators and SIRT1 were measured. Furthermore, human brain microvascular endothelial cells (HBMECs) were subjected to 3 h oxygen and glucose deprivation (OGD) followed by 24 h reoxygenation to mimic cerebral I/R in vitro. EX527 pre-treatment occurred 1 h before OGD. SIRT1 and inflammatory mediator levels were analyzed.
Both XNJ doses significantly decreased cerebral infarct area (40.11% vs. 19.66% and 9.87%) and improved neurological scores and morphological changes. Inflammatory mediator levels were remarkably decreased in both model systems after XNJ treatment. XNJ also enhanced SIRT1 expression. Notably, the SIRT1 inhibitor EX527 attenuated the XNJ-mediated decrease in inflammation in vivo and in vitro.
XNJ improved cerebral I/R injury through inhibiting the inflammatory response via the SIRT1 pathway, which may be a useful target in treating cerebral I/R injury.</description><subject>Cerebral blood flow</subject><subject>Cerebral infarction</subject><subject>Chinese medicine</subject><subject>Endothelial cells</subject><subject>Inflammation</subject><subject>Injection</subject><subject>Ischemia</subject><subject>Microvasculature</subject><subject>Morphology</subject><subject>pro-inflammatory response</subject><subject>Reperfusion</subject><subject>SIRT1 protein</subject><subject>stroke</subject><issn>1388-0209</issn><issn>1744-5116</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk1v1DAQhiMEoqXwE0CRuHDJ1t-xLwhU8bGoAgmKxM2ynfGuV0m8tZOiFX8eL7utKAdOtmaeecczfqvqOUYLjCQ6x1RKRJBaEITVAgslBVYPqlPcMtZwjMXDci9Ms4dOqic5bxBCnFL-uDqhWHJGCD-tfv0I4-qziZ_KUYdxA24KcazNAH2IyUyQawcJbDJ9HbJbGxiCOU-wheTnvEdL0Zx29U0w9bfl1yvcDNCFUtiVjO_NMJgplnyCvI1jhhJdBxv2XZ5Wj7zpMzw7nmfV9_fvri4-NpdfPiwv3l42jgsyNd5KpiRvQWLCLRPCW8bAA6XGtWCVY1aJTmJBgbaMqNYjSjtMWWt5x62lZ9XyoNtFs9HbFAaTdjqaoP8EYlppk6bgetDccUONJcRjxTqPrBPUiBZRYdqOSl60Xh-0trMtgzoYp7Kae6L3M2NY61W80UKJMgYuAq-OAilez5AnPZS9Qt-bEeKcNaFEtkxyRAr68h90E-c0llVpwpFiFGGsCsUPlEsx5wT-7jEY6b1V9K1V9N4q-miVUvfi70nuqm69UYA3B6D8Y0yD-RlT3-nJ7PqYfDKjC7nA_-3xG02e0Es</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Zhang, Yue-Ming</creator><creator>Qu, Xiao-Yu</creator><creator>Tao, Li-Na</creator><creator>Zhai, Jing-Hui</creator><creator>Gao, Huan</creator><creator>Song, Yan-Qing</creator><creator>Zhang, Si-Xi</creator><general>Taylor & Francis</general><general>Taylor & Francis Ltd</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1685-6914</orcidid></search><sort><creationdate>20200101</creationdate><title>XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition</title><author>Zhang, Yue-Ming ; Qu, Xiao-Yu ; Tao, Li-Na ; Zhai, Jing-Hui ; Gao, Huan ; Song, Yan-Qing ; Zhang, Si-Xi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c562t-fb849857e8125b466fb44efe33ac7eb9c4b96d8163e374297f033d1347b5d5bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cerebral blood flow</topic><topic>Cerebral infarction</topic><topic>Chinese medicine</topic><topic>Endothelial cells</topic><topic>Inflammation</topic><topic>Injection</topic><topic>Ischemia</topic><topic>Microvasculature</topic><topic>Morphology</topic><topic>pro-inflammatory response</topic><topic>Reperfusion</topic><topic>SIRT1 protein</topic><topic>stroke</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Yue-Ming</creatorcontrib><creatorcontrib>Qu, Xiao-Yu</creatorcontrib><creatorcontrib>Tao, Li-Na</creatorcontrib><creatorcontrib>Zhai, Jing-Hui</creatorcontrib><creatorcontrib>Gao, Huan</creatorcontrib><creatorcontrib>Song, Yan-Qing</creatorcontrib><creatorcontrib>Zhang, Si-Xi</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceutical biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Yue-Ming</au><au>Qu, Xiao-Yu</au><au>Tao, Li-Na</au><au>Zhai, Jing-Hui</au><au>Gao, Huan</au><au>Song, Yan-Qing</au><au>Zhang, Si-Xi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition</atitle><jtitle>Pharmaceutical biology</jtitle><addtitle>Pharm Biol</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>58</volume><issue>1</issue><spage>16</spage><epage>24</epage><pages>16-24</pages><issn>1388-0209</issn><eissn>1744-5116</eissn><abstract>XingNaoJing injection (XNJ), extracted from a traditional compound Chinese medicine Angong niuhuang pill, is well known for treating stroke in the clinic, but the specific effects and mechanisms remain unclear.
We investigated the mechanistic basis for the protective effect of XNJ on cerebral ischaemia/reperfusion (I/R) injury.
Five groups of 10 SD rats underwent 2 h of middle cerebral artery occlusion (MCAO) followed by 24 h reperfusion. XNJ at 10 and 15 mL/kg was intraperitoneally administered 24 h before ischaemia and at the onset of reperfusion respectively. The silent information regulator 1 (SIRT1) inhibitor EX527 was intracerebroventricularly injected 0.5 h before reperfusion. Cerebral infarction size, neurological scores, morphological changes, and expression levels of inflammatory mediators and SIRT1 were measured. Furthermore, human brain microvascular endothelial cells (HBMECs) were subjected to 3 h oxygen and glucose deprivation (OGD) followed by 24 h reoxygenation to mimic cerebral I/R in vitro. EX527 pre-treatment occurred 1 h before OGD. SIRT1 and inflammatory mediator levels were analyzed.
Both XNJ doses significantly decreased cerebral infarct area (40.11% vs. 19.66% and 9.87%) and improved neurological scores and morphological changes. Inflammatory mediator levels were remarkably decreased in both model systems after XNJ treatment. XNJ also enhanced SIRT1 expression. Notably, the SIRT1 inhibitor EX527 attenuated the XNJ-mediated decrease in inflammation in vivo and in vitro.
XNJ improved cerebral I/R injury through inhibiting the inflammatory response via the SIRT1 pathway, which may be a useful target in treating cerebral I/R injury.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>31854225</pmid><doi>10.1080/13880209.2019.1698619</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-1685-6914</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1388-0209 |
ispartof | Pharmaceutical biology, 2020-01, Vol.58 (1), p.16-24 |
issn | 1388-0209 1744-5116 |
language | eng |
recordid | cdi_crossref_primary_10_1080_13880209_2019_1698619 |
source | Taylor & Francis Open Access; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection |
subjects | Cerebral blood flow Cerebral infarction Chinese medicine Endothelial cells Inflammation Injection Ischemia Microvasculature Morphology pro-inflammatory response Reperfusion SIRT1 protein stroke |
title | XingNaoJing injection ameliorates cerebral ischaemia/reperfusion injury via SIRT1-mediated inflammatory response inhibition |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T18%3A16%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=XingNaoJing%20injection%20ameliorates%20cerebral%20ischaemia/reperfusion%20injury%20via%20SIRT1-mediated%20inflammatory%20response%20inhibition&rft.jtitle=Pharmaceutical%20biology&rft.au=Zhang,%20Yue-Ming&rft.date=2020-01-01&rft.volume=58&rft.issue=1&rft.spage=16&rft.epage=24&rft.pages=16-24&rft.issn=1388-0209&rft.eissn=1744-5116&rft_id=info:doi/10.1080/13880209.2019.1698619&rft_dat=%3Cproquest_cross%3E2509430119%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2509430119&rft_id=info:pmid/31854225&rft_doaj_id=oai_doaj_org_article_5c5a3ab22f194df0bc63a67036a7d385&rfr_iscdi=true |